These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2275477)

  • 1. Overview of gram-negative sepsis.
    Dudley MN
    Am J Hosp Pharm; 1990 Nov; 47(11 Suppl 3):S3-6. PubMed ID: 2275477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology and treatment of gram-negative sepsis.
    DiPiro JT
    Am J Hosp Pharm; 1990 Nov; 47(11 Suppl 3):S6-10. PubMed ID: 2275478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of monoclonal antibody therapy in the treatment of infectious disease.
    Chmel H
    Am J Hosp Pharm; 1990 Nov; 47(11 Suppl 3):S11-5. PubMed ID: 2275476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
    Gorelick KJ; Chmel H
    Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticore endotoxin F(ab')2 equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial sepsis.
    Dunn DL; Mach PA; Condie RM; Cerra FB
    Surgery; 1984 Aug; 96(2):440-6. PubMed ID: 6379963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gram negative sepsis and shock.
    Landesman SH; Gorbach SL
    Orthop Clin North Am; 1978 Jul; 9(3):611-25. PubMed ID: 358039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Projected impact of monoclonal anti-endotoxin antibody therapy.
    Bates DW; Lee TH
    Arch Intern Med; 1994 Jun; 154(11):1241-9. PubMed ID: 8203991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoprophylaxis and immunotherapy of Gram-negative infections in the immunocompromised host.
    Glauser MP; McCutchan JA; Ziegler E
    Clin Haematol; 1984 Oct; 13(3):549-55. PubMed ID: 6388931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003.
    Wu CJ; Lee HC; Lee NY; Shih HI; Ko NY; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2006 Apr; 39(2):135-43. PubMed ID: 16604246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies to endotoxin in the management of sepsis.
    Fang KC
    West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance and predictors of community-onset Pseudomonas aeruginosa bacteremia.
    Cheong HS; Kang CI; Wi YM; Kim ES; Lee JS; Ko KS; Chung DR; Lee NY; Song JH; Peck KR
    Am J Med; 2008 Aug; 121(8):709-14. PubMed ID: 18691485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Infection caused by gram-positive and gram-negative bacteria. A comparative study].
    Ruhnke-Trautmann M; Trautmann M; Brückner O; Weinke T; Wagner J
    Fortschr Med; 1989 Jul; 107(22):477-80. PubMed ID: 2793023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sepsis and septic shock.
    Zanetti G; Baumgartner JD; Glauser MP
    Schweiz Med Wochenschr; 1997 Mar; 127(12):489-99. PubMed ID: 9106949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common TNF-alpha, IL-1 beta, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis.
    Jessen KM; Lindboe SB; Petersen AL; Eugen-Olsen J; Benfield T
    BMC Infect Dis; 2007 Sep; 7():108. PubMed ID: 17877801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sepsis syndrome in a Dutch university hospital. Clinical observations.
    Kieft H; Hoepelman AI; Zhou W; Rozenberg-Arska M; Struyvenberg A; Verhoef J
    Arch Intern Med; 1993 Oct; 153(19):2241-7. PubMed ID: 8215727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody therapy for gram-negative sepsis: principles, applications, and controversies.
    Mehra IV; Gottlieb JE; Nash DB
    Pharmacotherapy; 1993; 13(2):128-34. PubMed ID: 8469619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiology of septic shock and implications for therapy.
    Barron RL
    Clin Pharm; 1993 Nov; 12(11):829-45. PubMed ID: 8161370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Monoclonal antibodies in the treatment of sepsis caused by Gram-negative microorganisms].
    Otero AJ; Linares M
    Rev Cubana Med Trop; 1998; 50(1):31-5. PubMed ID: 9842265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gram-hegative bacillemia.
    McHenry MC; Hawk WA; Straffon RA
    Urol Clin North Am; 1976 Jun; 3(2):333-51. PubMed ID: 822557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.